CMP Therapeutics appoints ceo

Receives loan to support clinical trial of lead product for common cold

London-based CMP Therapeutics (CMPT) has appointed Neill Moray Mackenzie as chief executive.

Mackenzie joins the developer of therapeutics for colds, flu and allergy with a long record of executive board level management within the biotechnology and pharmaceutical industries at companies including Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore). He was most recently SVP for business development and corporate strategy at Medigene and ceo of Roji (London). In addition, MacKenzie was formerly a departmental head in vaccine r&d at Wellcome and a Wellcome lecturer in immunology at the University of London.

CMPT has received €1.5m convertible loan from Inventages Venture Capital to support continuing operations and the upcoming clinical trial of its lead product for the common cold. CMPT has been supported funding from London-based Inventages Venture Capital and New Zealand-based BioPacificVentures since 2005.

You may also like

Research & Development

OGT launches new SureSeq myeloid fusion panel drive myeloid cancer research

The assay enables users to integrate research techniques with a single, streamlined NGS process, expediting the process
Regulatory

Compact process thermostat for efficient temperature control in the lab

The Petite Fleur allows for laboratory reactor temperature control between -40 °C to +200 °C with a 480W refrigeration capacity
Research & Development

Lonza's AI-enabled small molecule development tool launches

The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Manufacturing

Miltenyi Biotec and MiLaboratories collaborate to advance next-generation therapies

Miltenyi Biotec will commercialise MiLaboratories' RNA kit technology for immune sequencing, facilitating advances in the field of personalised medicine
Research & Development

Abzena launches EpiScreen 2.0 to assist the development of complex biologics and bioconjugates

The updated platform delivers an advanced range of immune response measurements, while also providing information on mechanism-of-action and specificity
Research & Development

COVID-19 still a significant risk for the immunocompromised, study finds

AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Research & Development

N4 Pharma and SRI to target and treat previously unreachable human cells

The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Subscribe now